Avicanna CEO Aras Azadian joins Natalie Stoberman from the Proactive studio to talk about last year's milestones for a Year in Review.
Azadian says 2022 was a challenging year for the global economy including both the biopharmaceutical and cannabis industries. Despite the challenges, Azadian explains it was transformational year at Avicanna where they were still able to stay focused and deliver on its business plan.
Avicanna's aim in 2022 was to commercialize and advance the intellectual property portfolio across our 4 business units: Active Pharmaceutical Ingredients, Cosmetics, Medical, and Pharmaceutical, which have contributed to successful exports to 18 international markets.
#proactiveinvestors #avicanna #TSX #AVCN #OTCQX #AVCNF #cannabis #medicalcannabis #hemp #thc #cbd #investors